Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

SELL
$0.97 - $1.24 $6,499 - $8,308
-6,700 Reduced 39.7%
10,178 $9,000
Q4 2024

Feb 14, 2025

BUY
$0.84 - $1.69 $14,177 - $28,523
16,878 New
16,878 $19,000

Others Institutions Holding ENLV

About Enlivex Therapeutics Ltd.


  • Ticker ENLV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,403,200
  • Market Cap $28.9M
  • Description
  • Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...
More about ENLV
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.